Ocean Biomedical’s (NASDAQ: OCEA) mRNA-based Vaccine Candidate Generates Over 90% Killing of Malaria Parasites in Non-human Primates, Demonstrating Broad Potential for Ocean’s Program to Address Global and Emerging U.S. Malaria Challenges
Providence, RI, July 11, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: OCEA), a biopharma company working to accelerate the development of compelling discoveries from top research scientists, announced today that it is focusing its multi-pronged malaria program to address the chronic malaria crisis in sub-Saharan Africa while recognizing newly emerging global malaria challenges.
- Based on discoveries by Scientific Co-founder, Jonathan Kurtis, MD, PhD, Ocean Biomedical is working on a multivalent mRNA-based malaria vaccine with potential to target several stages in the malaria cycle.
- Additionally, the company has discovered a new therapeutic approach with the potential to launch a whole new class of anti-malarials.
- Multiple U.S. and global patents are held by Ocean Biomedical for both the vaccine and therapeutic approaches.
- Ocean Biomedical’s novel malaria vaccine program is based on groundbreaking discoveries by Dr. Kurtis that have revealed new insights into how malaria parasites maintain homeostasis in their hosts.